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Abstract:		
Objective: We investigated whether rituximab, an anti-B-cell therapy, improved symptoms 
of fatigue and oral dryness in patients with Primary Sjogren’s Syndrome (PSS). 
Methods: Multicentre, randomised, double-blind, parallel-group placebo-controlled trial, 
including Health Economic Analysis. Anti-Ro positive patients with PSS, symptomatic fatigue 
and oral dryness were recruited from 25 UK rheumatology clinics from June 2012 to January 
2014. Patients were centrally-randomised to either placebo IV or rituximab IV (1000mg in 
250mL) at weeks 0, 2, 24 and 26, with pre-and post-infusion medication including 
corticosteroids. Primary endpoint was the proportion of patients achieving 30% reduction in 
either fatigue or oral dryness at 48 weeks, measured by Visual Analogue Scale. Other 
outcomes included salivary and lachrymal flow rates, quality of life, ESSDAI and ESSPRI, 
symptoms of ocular and overall dryness, pain, global disease assessment and cost-
effectiveness. ISRCTN 65360827 
Results: All patients (n=133) randomised to placebo (n=66) and to rituximab (n=67) were 
included in the primary analysis. Among complete cases, 21/56 placebo and 24/61 rituximab 
patients achieved primary endpoint. After multiple imputation of missing outcomes, 
placebo and rituximab response rates were 36·8% and 39·8%, respectively (adjusted odds 
ratio 1·13 95% CI 0·50-2·55).  There were no significant improvements in any outcome 
measure, except unstimulated salivary flow. Mean (SD) costs for rituximab and placebo 
were £10,752 (SD 264·75) and £2,672 (SD 241·71). There were slightly more adverse events 
reported in total for rituximab, but no difference in serious adverse events (ten in each 
group). 
Conclusions: Rituximab is neither clinically or cost-effective in this patient population.  
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Introduction	
Primary Sjögren’s Syndrome (PSS) is a common auto-immune rheumatic condition, second 
only in frequency to rheumatoid arthritis (RA) (1). PSS patients are typically female (9:1 
female:male ratio) with prevalence estimated between 1 and 6 per 1,000 adult women. 
Typical symptoms of PSS are oral and ocular dryness, fatigue and pain. Fibromyalgia is also 
reported in 5% of PSS patients, comparable in frequency to its prevalence in Systemic Lupus 
Erythematosus. (2) Organ-specific systemic involvement is observed in 5-20% of patients 
and includes cutaneous involvement, peripheral neuropathy, non-erosive arthritis, 
interstitial cystitis, lung and renal disease. These patients almost always have evidence of B-
cell hyper-reactivity with anti-Ro/La antibodies & hypergammaglobulinaemia. 
Currently, PSS treatment focusses on relieving symptoms, rather than altering the course of 
the disease. For ocular dryness, artificial tears are reasonably effective. For oral dryness, 
however, symptomatic therapies (sprays, lozenges, pastilles) have limited efficacy. 
Pilocarpine has been shown to alleviate symptoms of dryness (3, 4). However, the utility of 
pilocarpine is generally considered to be limited, and its side effects reduce the risk-benefit 
profile. There is no effective therapy for fatigue.  
In the absence of positive clinical trial data, treatment of systemic PSS is empirical. 
Hydroxychloroquine and/or low dose prednisolone are often used in mild disease (although 
recent findings from the JOQUER study suggest limited benefit (5)). For severe disease, such 
as progressive neuropathy, intravenous (IV) methylprednisolone, cyclophosphamide, 
azathioprine, ciclosporin, mycophenolate or chlorambucil may be used. In B-cell lymphoma, 
it is routine to treat with combination chemotherapy plus rituximab. 
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Rituximab is a monoclonal antibody against CD20, (a cell surface antigen expressed on B 
cells).  Treatment with rituximab induces a rapid and sustained depletion of B cells. 
Rituximab is currently approved for the treatment of relapsed or refractory non-Hodgkin’s 
lymphoma, chronic lymphocytic leukaemia, and in combination with methotrexate for the 
treatment of RA patients. 
Evidence from small prospective uncontrolled open-label studies of rituximab in PSS have 
shown improvements in patient-reported levels of dryness, pain, fatigue, global assessment, 
SF36 scores (6), stimulated salivary flow (7) and physician global assessment (8). A 
prospective study comparing symptom levels over ten years of follow-up between patients 
receiving rituximab in one hospital and disease modifying anti-rheumatic drugs (DMARD) in 
another found superior improvements for rituximab compared to DMARD therapy. (9) 
Findings from small double-blind randomised placebo-controlled trials have also provided 
some cause for optimism in terms of improved fatigue improvement (10) and improvements 
in ocular dryness (11). More recently, however, in the TEARS study (12), there was no 
significant difference in the proportions of patients achieving the primary endpoint 
(absolute improvement of 30mm or more in 2 of 4 Visual Analogue Scales (VAS) measuring 
fatigue, dryness, pain and global assessment) at 24 weeks, although a greater response in 
terms of fatigue was demonstrated at earlier time-points.  
As evidence from randomised trials has only assessed the efficacy of a single course of 
rituximab, there remains a gap in the clinical knowledge for a randomised, double-blind 
evaluation of a follow-up dose of rituximab in patients with PSS. The TRACTISS trial was 
designed to determine the effectiveness of rituximab in improving symptoms of fatigue or 
oral dryness in patients with PSS following two courses of therapy.  
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Patients	and	Methods:	
TRACTISS (ISRCTN: 65360827, EudraCT Number: 2010-021430-64) is a randomised, 1:1, 
parallel-group, double-blind, multicentre, placebo-controlled trial, to determine the 
effectiveness of rituximab in alleviating patient-reported symptoms of fatigue and oral 
dryness, in patients with PSS. The trial was carried out in accordance with Good Clinical 
Practice, and the Declaration of Helsinki. Ethical and governance approval were obtained 
from the Leeds West Ethics Committee (ref 10/H1307/99) and the Leeds Teaching Hospitals 
NHS Trust respectively. An independent Data Monitoring and Ethics Committee (DMEC) had 
access to ongoing unblinded reports of safety and compliance, and a Trial Steering 
Committee (TSC) had overall oversight of the study. 
The TRACTISS protocol has been published (13). Briefly, between June 2012 and January 
2014, participants were recruited from 25 UK rheumatology clinics, and were eligible if they 
had PSS, were aged 18-80 years, positive for Anti-Ro autoantibodies, had some (greater 
than zero) unstimulated salivary flow, symptomatic fatigue and oral dryness worse than 
5/10 on a patient-completed Likert scale, on a stable dose of corticosteroids, NSAIDS, 
DMARDS, pilocarpine and antidepressants for 4 weeks prior and throughout the study and 
provided written informed consent to participate. Exclusion criteria included Secondary 
Sjögren’s Syndrome, Hepatitis B or C, tuberculosis, HIV or other immunodeficiency, prior 
rituximab or monoclonal antibody usage, malignancies within 5 years prior, recent organ 
transplant, major surgery planned or 3 months prior,  pregnancy / lactation and 
unwillingness to use contraception throughout the study. Eligibility criteria originally 
required patients receiving hydroxychloroquine to be on a stable dose prior to starting and 
patients with benign ethnic neutropaenia were also excluded. These criteria were relaxed 
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during the study to clarify inconsistent criteria and to avoid excluding otherwise well 
patients, respectively. 
Participants received either rituximab IV (1000mg in 250mL saline) or placebo IV (250mL 
saline) in 2 courses at weeks 0, 2, 24 and 26. To reduce risk of infusion reactions, patients 
received pre-infusion medication of methylprednisolone, acetaminophen and 
chlorphenamine and post-infusion oral prednisolone, reducing from 60mg to 15mg over 7 
days post infusion. (13) 
At baseline and weeks 16, 24, 36 and 48, patients completed VAS Questionnaires recording 
Fatigue, Overall Dryness, Oral Dryness, Ocular Dryness, Pain and Global Assessment 
(average symptom level over previous 2 weeks: 0=None, 100mm=Severe) and the ESSPRI. 
PROFAD-SSI, SF36 and EQ5D-3L questionnaires were completed at baseline and weeks 24 
and 48. Physicians completed ESSDAI and Global Assessment of Disease Activity at all visits, 
and the SSDAI, SSDI, SSDDI, SCAI and the Global Assessment of Damage at Baseline and 
weeks 24 and 48. (13) 
Randomisation was by 24-hour central telephone service operated by the Clinical Trials 
Research Unit. Consenting participants were registered before undergoing further clinical 
tests to ensure eligibility. Once eligibility was confirmed, participants were allocated by 
minimisation, which assigned a patient with 80% probability to the arm that reduced the 
between-group imbalance in randomising centre, age category, years since diagnosis, 
consent for ultrasound and for biopsy sub-studies.  
Each site’s dispensing pharmacy received details of the participant allocation by fax to 
facilitate infusion preparation. On the day of infusion, pharmacy provided either a pure 
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saline bag (placebo) or a saline bag to which rituximab had been added. A small volume of 
saline was withdrawn from rituximab bags, to ensure no difference in bag volume was 
detected. Placebo and rituximab infusion bags were otherwise identical. 
The primary endpoint was the achievement of a reduction of at least 30% relative to the 
baseline measurement in the patient-completed VAS assessments of either fatigue or oral 
dryness at week 48. Secondary endpoints included the patient-completed and physician-
completed assessments at other time-points and measurements of Salivary and Lachrymal 
Flow. The primary endpoint was modelled using mixed-effects logistic regression, with 
stratification factors as fixed effects (except for the randomising centre, fitted as a random 
effect) and a fixed effect for the randomised treatment arm. All patients were included in 
this primary analysis, even if the patient had incomplete outcome data. For patients with 
incomplete primary endpoint questionnaire data (fatigue and oral dryness each at baseline 
and week 48), we used multiple imputation by chained equations (14) to impute plausible 
missing VAS values as a function of the fixed randomisation factors (for baseline values) and 
also the baseline values (for week 48 values). Missing values were imputed separately for 
each scale, both for placebo and for rituximab patients to produce one full dataset. This was 
repeated N times where N was the number of patients with incomplete data. Analysis was 
performed for each dataset, and the results combined to estimate treatment effects and 
appropriate confidence intervals using Rubin’s rules (15). To assess sensitivity of results to 
alternative assumptions about missing data, we repeated the analysis using a Last 
Observation Carried Forward approach, a complete-case analysis and a per-protocol 
population analysis. In order to calculate adjusted absolute differences in response rates, 
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we fitted a linear probability model (binary error structure with identity link function); we 
excluded the random centre effect from this model to ensure model convergence. 
Secondary endpoints were analysed by fitting a random-coefficients mixed effects linear 
regression model with fixed effects for baseline value, age, disease duration, the sub-study 
consent, time and time-by-treatment interaction, and random effects for patient and 
patient-by-time interaction, taking the time to be the number of weeks since randomisation. 
Most endpoints were analysed on their original scale, though we logarithm-transformed the 
salivary and lachrymal flow rates and the ESSDAI (including an offset to avoid zero values) to 
better approximate normality. We repeated this longitudinal analysis using a covariance 
pattern type mixed model, treating assessments as discrete sequential observations 
(relaxing the assumption of a linear treatment effect) so as to provide graphical summaries 
of group means at each time-point using least-squares means.  
The pre-defined minimum clinically important effect of rituximab was an increase in 
treatment response rate from 20% in the placebo arm to 50% in the rituximab arm. For a 
two-sided continuity-corrected Chi-Squared test, 50 patients with complete data in each 
arm were needed in order to have 80% power to detect this difference at a 5% significance 
level. To allow for non-completion, 110 patients (55 per arm) were required. 
In July 2013, the DMEC recommended extending recruitment until the end of the planned 
recruitment period and a protocol amendment allowed participants to complete the final 
primary endpoint questionnaire at home, rather than attending clinic, to reduce loss to 
follow-up. 
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An economic evaluation was conducted alongside the clinical trial to assess cost-
effectiveness of rituximab compared to placebo over 48 weeks. Incremental cost-
effectiveness ratios (ICERs) were calculated using the willingness to pay threshold of 
£20,000 per Quality-Adjusted-Life-Year (QALY) gain (16). QALYs were calculated using utility 
weights derived from the EQ-5D-3L collected at 16, 24, 36 and 48 weeks post-randomisation 
(17). Resource use was captured using bespoke patient-completed forms and nurse records 
of medications and hospital visits. Costs were attached to individuals employing NHS 
Reference costs, Personal Social Services Research Unit and British National Formulary 
databases (price year 2014) (18-20). Analyses were conducted from the perspective of the 
healthcare provider. The probability of cost-effectiveness was determined by bootstrapping 
and constructing cost-effectiveness acceptability curves using a range of willingness to pay 
thresholds for QALY gains (21). Multiple imputation was employed to account for missing 
cost and EQ-5D data (22). No discounting was undertaken, due to the short follow-up 
duration of 48 weeks per patient. 
 
Results	
Recruitment 
Between June 2012 and January 2014, 133 participants were randomised 1:1 to receive 
either rituximab or placebo (Figure 1). Final follow-up visit was completed by January 2015. 
Randomised patients were, on average, 54 years old (SD 11) with 23% (30/133) aged 65 or 
older, were 5·7 (SD 5·4) years post diagnosis (24/133, 18% with 10 or more years) and 124 
(93.2%) were female. Baseline characteristics of patients are presented in Table 1.  
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Primary Endpoint Analysis 
All 66 placebo (PLC) and 67 rituximab (RTX) patients were included in the primary endpoint 
analysis. Sixteen participants (12.0%) had incomplete fatigue or oral dryness measurements 
at baseline (1PLC, 1RTX) or at week 48 (9PLC, 5RTX). The primary endpoint response rates 
were, among complete cases, 21/56 (37·5%) for placebo patients and 24/61 (39·3%) for 
rituximab patients. After multiple imputation of missing responses, the mean response rates 
were 36·8% and 39·8% for placebo and rituximab arms (unadjusted absolute difference RTX-
PLC 3·0% 95%CI: -14·5 to 20·5%). In the primary analysis, rituximab patients were not 
significantly more likely to achieve 30% reduction in fatigue or oral dryness than placebo 
patients (odds ratio 1·1; 95% CI 0·5 to 2·5; P=0·76). The baseline-adjusted absolute 
difference in response rates (RTX-PLC) was 1·7% (95% CI -16·5 to 19·1%; P=0·84). The lack of 
significant treatment effect remained even when using different endpoint imputation 
strategies, or a complete case analysis. A per-protocol population analysis (excluding 
patients found to be ineligible, those not receiving all 4 doses within a reasonable 
timeframe and those with incomplete primary endpoint data) was also not significant (odds 
ratio 0·9; 95% CI 0·1 to 6·5; P=0·95). 
Secondary Endpoints 
Longitudinal analyses of patient VAS scales did not reveal significant differences in change 
over time between randomised arms for any of the six VAS scores. Figure 2 (A and B) 
illustrates the levels of symptomatic fatigue and oral dryness reported over time; there 
were no significant differences between the groups at any time-point for these, or any of 
the other symptom scales (Online Supplement Figure D1). 
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Composite disease activity scores, and patient-reported outcome measures showed no 
benefit for rituximab. There was no significant difference between the two groups over time 
in the average ESSPRI or the ESSDAI scales (except for a small relative difference in ESSDAI 
scores at week 36 in favour of rituximab) (Table 2). There was no improvement in any 
domain of the SF-36 for rituximab over placebo, nor in the SF-36 component scores. There 
was also no improvement in the PROFAD-SSI domains at any time-point for rituximab 
compared to placebo. 
We did observe a difference between the arms in unstimulated salivary flow. Over the 
duration of follow-up, we found that the log-transformed USF values seemed to hold 
constant for rituximab patients, and to deteriorate for placebo patients. Although the 
treatment-by-time interaction effect was not statistically significant at traditional thresholds 
(estimate: 0·013, 95% CI (-0·001 to 0·028), P=0·066) the between-group differences 
between the mean values of USF at weeks 36 and 48 were statistically significant (Table 2, 
Figure 2C). No similar benefit was seen in stimulated salivary flow or in mean lachrymal flow 
(Figure 2D). 
We performed four post-hoc subgroup analyses to investigate treatment modification effect 
due to baseline ESSDAI scores (using two different thresholds), baseline ESSPRI scores and 
the disease duration since diagnosis (Table 3). No significant treatment modification effect 
was observed in any of these subgroup analyses. 
Cost effectiveness 
The mean costs and QALY estimates by trial arm at 48 weeks are included in Appendix Table 
B1. When excluding the rituximab infusion no significant difference in resource use between 
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treatment arms was observed. However inclusion of the rituximab infusion conferred 
significant differences in costs between arms. The mean cost per patient in the rituximab 
arm was £10,752 (SD 264·75) compared to £2,672 (SD 241·71) for the placebo arm. Mean 
QALYs were 0·55 (SD 0·003) and 0·56 (SD 0·004) for rituximab and placebo groups 
respectively. The higher mean costs, and lower QALYs mean that placebo dominates 
rituximab (Appendix figure B1). Bootstrapping the mean costs and QALYs suggested that 
rituximab had a 0% probability of being cost-effective at any threshold from £0 to £200,000.  
Safety 
Rituximab was well-tolerated among patients. There were no deaths in either arm, ten 
serious adverse events (SAE) among nine patients in each arm - of which three events in 
three patients were serious adverse reactions (Table 4). One participant randomised to 
rituximab did not receive any rituximab prior to having a SAE. One serious infusion reaction 
was reported in one patient receiving rituximab, and one serious Anaphylaxis event was 
reported in one patient receiving placebo.  
 
Discussion	
TRACTISS is the largest randomised placebo-controlled trial of rituximab in patients with 
primary Sjögren’s Syndrome. After two courses, each comprising 2 doses of 1000mg of 
rituximab, patients were not significantly more likely to report a response to treatment at 
the 48 week time-point (in terms of a reduction of 30% of baseline measurement in either 
Oral Dryness or Fatigue VAS) than those randomised to receive placebo. These scales, and 
others for the patients’ Ocular and Overall Dryness, Joint Pain and Global Assessment of 
disease activity were not significantly improved by rituximab at any time-point. We also did 
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not observe a significant benefit in terms of lachrymal flow, or in any of the composite 
patient-reported outcomes, or disease activity indices, except for a one-off significant 
difference between groups in the ESSDAI score at week 36. We did observe significant 
differences between the groups in average Unstimulated Salivary Flow rates; rituximab 
patients maintained their baseline flow rate, while placebo patients decreased. No 
difference in the safety profile for the two arms was observed. 
For the economic analyses a small non-significant difference in QALYs was observed 
between the arms in favour of the placebo. The main driver of costs was the rituximab 
infusion which attracted a cost of £1,746 per 1000mg and a significantly higher overall cost 
compared with placebo. There was no significant difference in costs when rituximab was 
excluded. Further analysis revealed that even at a willingness-to-pay threshold ten times 
higher than the current NICE recommendation (16) rituximab was not cost effective; even 
with a relatively large reduction in price the use of rituximab is unlikely to be cost effective. 
TRACTISS is the fourth double-blind placebo-controlled randomised trial of rituximab 
reported to date, bringing the total number of patients included in such studies to 302. The 
first study, a pilot RCT in 17 patients (10) reported an greater reduction in fatigue among 
patients randomised to rituximab compared to those receiving placebo, but no significant 
difference in proportions of patients achieving either 20% or 30% reduction from baseline in 
fatigue at 6 months. A later RCT in 30 patients (11) reported significant changes from 
baseline for most variables (including salivary flow rates and patient-reported measures of 
fatigue, oral and ocular dryness) in both arms, but the 20 rituximab patients only reported 
significant differences to the 10 placebo patients in Stimulated Salivary Flow at 12 weeks, 
and in ocular dryness at 36 and 48 weeks.  
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Most recently, the TEARS study (12) analysed 120 patients randomised to either rituximab 
or placebo in a multicentre trial and did not detect a significant difference in numbers of 
patients achieving the primary endpoint (reductions of 30mm in at least 2 VAS for Dryness, 
Pain, Fatigue and Global Assessment). Although a significant response was detected at 6 
weeks, particularly in fatigue, this was not sustained by the 24 week time-point. Signs of 
efficacy were evident in fatigue and dryness when these outcome data were analysed 
longitudinally, but symptoms of Pain and Global assessment were not significantly 
improved. As in previous studies, TEARS found no significant difference in the safety profiles 
of the arms.  
TRACTISS differed from these randomised trials in that patients were randomised to two 
doses of the trial drug, to be received in a double-blind manner. It was hoped that signals of 
efficacy observed in earlier studies would be seen at the same time-points in TRACTISS, and 
that a second dose would demonstrate long-term efficacy of rituximab. However, early 
efficacy measured by fatigue at 16 weeks (TEARS) and late efficacy in terms of ocular 
dryness (Meijer et al) were not observed in TRACTISS. Similarly, although we observed 
significant deterioration in unstimulated salivary flow for placebo compared to rituximab, at 
later time-points, no such effect was reported in other RCTs.  
Evidence from non-randomised trials and uncontrolled studies was more promising. In an 
open-label prospective study (9), 19 patients at one centre received rituximab, and 22 
patients at another received DMARD therapy over a 10 year period. Patients in this study 
had higher disease activity (mean baseline ESSDAI score was 20).  Significant differences 
between the two arms was demonstrated in Fatigue and Dryness VAS scores (week 120 
mean (SEM) fatigue DMARD 51·8 (4·5) vs RTX 41·1 (4·2); week 120 mean (SEM) Dryness 
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DMARD 51·8 (11·1) RTX 25·1 (7·7)), as well as ESSDAI (week 120 mean (SEM) DMARD 8·8 
(1·7) vs RTX 5·2 (0·9)), Unstimulated Salivary Flow (DMARD 0·1 (0·08) vs RTX 0·4 (0·04)) and 
Lachrymal flow (DMARD 5·5 (0·8) vs RTX 7·3 (0·8)). However, bias due to potential 
differences between centres’ practices, the open label nature of the study, and the differing 
additional study medications (DMARD & prednisone vs RTX & chlorphenamine, paracetamol 
and methylprednisolone) cannot be ruled out. Sixteen patients who received rituximab in an 
uncontrolled study (23) reported significant improvements from baseline in SF-36 
component scores (Mean Physical and Mental Component Summary improvements of 16·9 
and 31·2, respectively), but no such improvement was found in either our study (Table 2) or 
in the TEARS study. 
Researchers have previously suggested (5, 12) that outcome measures used in studies of 
these patients are not sufficiently sensitive to changes in the patient condition after 
successful treatment. To that end, composite outcome measures to be completed by the 
physician (24) and by the patient (25) were developed by the European League Against 
Rheumatism (EULAR). These  outcome measures were developed in patient populations of a 
similar age to those in TEARS and TRACTISS, but the development population profiles for 
both tools involved patients with slightly longer disease durations (approximately 8·5 years) 
than seen here. Moerman et al computed ESSDAI scores for all patients in one RCT (26) to 
conclude that the ESSDAI was sensitive enough to detect a treatment effect of rituximab, 
despite low average ESSDAI scores. In both TEARS and TRACTISS, patients had low ESSDAI 
scores at baseline (relative to the maximum score of 123) and mean improvement in ESSDAI 
was not different between the two arms. The ESSPRI did not suffer the same problem as the 
ESSDAI in TRACTISS, but no significant difference was detected overall, nor did it define a 
Page 20 of 52
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
20 
subgroup that demonstrated a benefit. A recent re-analysis of data from TEARS (27) 
proposed a data-driven composite outcome measure, the Sjögren’s Syndrome Responder 
Index (SSRI), rooted in the assumption that rituximab is effective. Data from TRACTISS may 
assist in the external validation of the SSRI. 
A post-hoc analysis of data from the TEARS study (28) to estimate the required sample size 
to detect a significant difference in response rates suggested that the most sensitive 
endpoint by which response to treatment can be assessed would be change in ultrasound 
grading. However, the observed ultrasonography improvement in TEARS (29) did not 
translate into patient-reported symptomatic improvement. Findings of the TRACTISS 
ultrasound sub-study will be presented at a later date, as will results of the labial gland 
biopsy sub-study. 
Despite being required to demonstrate a minimum level of symptomatic fatigue and oral 
dryness to take part in TRACTISS, the patients were mostly of recent onset and had mild 
systemic disease activity as measured by the ESSDAI. Although the two courses of rituximab 
given constituted a different treatment regimen to the single course in other RCTs, it 
remains a possibility that a benefit to patients would be seen if rituximab is administered 
over longer periods of time, such as those seen in longer open-label comparative studies. 
Further, although TRACTISS is the largest trial of rituximab in PSS to date, a sample size of 
133 patients is small by the standards of Phase III randomised trials, and confidence 
intervals around our estimates were wide. The low population prevalence of PSS poses 
challenges to recruitment, and emphasises the importance of patient retention, to ensure 
that studies are adequately powered.  
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Despite ambitions towards meta-analysis with data from the TEARS study, our study 
omitted a 6 week assessment visit, which was the time-point at which the greatest fatigue 
response was observed in TEARS. We omitted this visit to reduce the patient burden. 
Although our study had low levels of patient withdrawal (and used multiple imputation to 
account for uncertainty due to incomplete data) it was necessary to offer mailed 
questionnaires to some participants to capture primary endpoint data at 48 weeks.  
Like the TEARS trial, TRACTISS was designed to have power to detect a large difference in 
response rates between the arms: the possible side-effects due to rituximab, as well as the 
underlying inconvenience and costs of rituximab administration mean that a suitably large 
benefit would need to be demonstrated for rituximab to be worthwhile. The existence of a 
smaller long-term effect cannot be ruled out – and may be identified in a possible meta-
analysis – but it remains to be seen if a smaller effect would be worthwhile. 
Although there did not appear to be any excess risk due to rituximab, the results of the 
TRACTISS trial do not support the general use of rituximab in treating PSS, particularly in 
patients with recent disease onset and / or low disease activity. Meta-analysis with the 
TEARS study may improve overall precision of findings, but it seems unlikely that the 
combined results will identify a worthwhile treatment benefit. The need for further large 
randomised trials to demonstrate longer-term benefit appears questionable, since the lack 
of effect of 2 courses of rituximab seems in line with the lack of benefit of one course in 
randomised trials. Rituximab may still have a role in treating PSS patients with high levels of 
systemic disease activity who have failed to improve following conventional 
immunosuppressive therapy.  
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Tables	
Table	1:	Selected	Baseline	Characteristics		
(Values are Mean and standard deviation unless otherwise stated) 
 Placebo 
(N=66) 
Rituximab 
(N=67) 
All 
(N=133) 
Age (Years) 54·4 (11·6) 54·3 (11·5) 54·4 (11·5) 
Aged 65 years or older: n (%) 15 (22·7) 15 (22·4) 30 (22·6) 
Years since diagnosis 6·2 (5·8) 5·3 (4·9) 5·7 (5·4) 
10 or more years since diagnosis: n (%) 13 (19·7) 11 (16·4) 24 (18·0) 
Female Sex: n (%) 61 (92·4) 63 (94·0) 124 (93·2) 
Current Medications (prior to randomisation)    
 Pilocarpine: n (%) 3 (4·5%) 11 (16·4%) 14 (10·5%) 
 Hydroxychloroquine: n (%) 35 (53·0%) 39 (58·2%) 74 (55·6%) 
 Corticosteroids: n (%) 12 (18·2%) 7 (10·4%) 19 (14·3%) 
 NSAIDS: n (%) 16 (24·2%) 19 (28·4%) 35 (26·3%) 
Unstimulated Salivary Flow (mL/15min) 1·2 (1·8) 1·2 (1·2) 1·2 (1·5) 
Mean Lachrymal Flow (Schirmers I) (mm/5min) 8·2 (11·3) 6·6 (8·8) 7·4 (10·2) 
IgG (g/L) 17·7 (7·9) 18·4 (7·3) 18·0 (7·5) 
IgA (g/L) 3·4 (2·2) 3·0 (0·9) 3·2 (1·7) 
IgM (g/L) 1·2 (0·6) 1·3 (0·6) 1·2 (0·6) 
Anti-Ro autoantibody positive 66 (100·0%) 66 (98·5%) 132 (99·2%) 
Reduced C4 9 (13·6%) 10 (14·9%) 19 (14·3%) 
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Current Smoker: n (%) 8 (12·1) 3 (4·5) 11 (8·3) 
Visual Analogue Scales (Average over last 2 weeks, 
mm. 100=Severe, except Global) 
   
 Fatigue  74·6 (15·3) 71·2 (16·8) 72·8 (16·1) 
 Oral Dryness  77·3 (17·0) 75·3 (15·3) 76·3 (16·2) 
 Ocular Dryness  72·0 (19·6) 69·4 (20·9) 70·7 (20·2) 
 Overall Dryness  76·3 (16·3) 74·2 (15·4) 75·2 (15·8) 
 Joint Pain  57·5 (28·7) 52·0 (27·2) 54·7 (28·0) 
 Global Assessment (100=SS very active) 70·7 (17·8) 68·6 (18·0) 69·7 (17·9) 
ESSPRI (10=Maximal Symptom Severity) 6·7 (1·6) 6·4 (1·6) 6·6 (1·6) 
ESSDAI (123=Maximal Disease Activity) 6·0 (4·3) 5·3 (4·7) 5·7 (4·5) 
SF-36 Physical Component Score 35·6 (10·9) 36·6 (9·8) 36·1 (10·3) 
SF-36 Mental Component Score 40·7 (12·3) 39·2 (11·6) 40·0 (11·9) 
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Table	2:	Summaries	of	secondary	outcomes	adjusted	for	baseline	measurement.	
Values	are	Mean	(Standard	Error	of	Mean)	and	Mean	Difference	(95%	Confidence	
Interval)	from	covariance	pattern	model	
 Time-point 
in weeks 
Placebo 
(SEM) 
Rituximab 
(SEM) 
Difference (RTX – PLC, adjusting 
for baseline values) (95% 
Confidence Interval) 
Wald P-Value 
Fatigue Visual Analogue Scale 
 16 65·2 (3·4) 65·4 (3·2) 0·16 (-7·79, 8·10) 0·9693 
 24 64·9 (3·4) 69·5 (3·0) 4·67 (-2·87, 12·22) 0·2241 
 36 68·2 (3·3) 65·7 (3·7) -2·54 (-11·19, 6·11) 0·5639 
 48 65·8 (3·3) 67·9 (3·3) 2·10 (-5·89, 10·09) 0·6053 
Oral Dryness Visual Analogue Scale 
 16 69·0 (3·1) 65·7 (3·2) -3·28 (-10·50, 3·94) 0·3725 
 24 70·1 (3·2) 70·2 (3·3) 0·09 (-7·46, 7·64) 0·9821 
 36 65·7 (3·4) 58·3 (4·0) -7·33 (-16·35, 1·69) 0·1110 
 48 70·5 (3·0) 66·4 (3·7) -4·06 (-12·01, 3·89) 0·3157 
ESSDAI (Log-transformed 
a
) 
 16 4·1 (1·1) 3·4 (1·1) 0·85 (0·64, 1·11) 0·2234 
 24 4·4 (1·1) 4·1 (1·1) 0·94 (0·73, 1·22) 0·6549 
 36 4·8 (1·1) 3·5 (1·1) 0·74 (0·55, 0·98) 0·0352 
 48 4·5 (1·1) 3·4 (1·1) 0·75 (0·55, 1·03) 0·0721 
ESSPRI 
 16 6·3 (0·3) 6·5 (0·3) 0·19 (-0·45, 0·82) 0·5682 
 24 5·8 (0·2) 6·3 (0·2) 0·55 (0·01, 1·09) 0·0458 
 36 6·4 (0·3) 6·2 (0·3) -0·21 (-0·90, 0·49) 0·5622 
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 48 5·7 (0·2) 6·3 (0·3) 0·54 (-0·12, 1·20) 0·1087 
Unstimulated Salivary Flow (mL/15min) (Log-transformed 
a
) 
 16 0·6 (1·1) 0·9 (1·1) 1·36 (0·99, 1·88) 0·0583 
 24 0·7 (1·1) 0·8 (1·1) 1·25 (0·91, 1·72) 0·1742 
 36 0·6 (1·2) 1·0 (1·1) 1·56 (1·11, 2·18) 0·0103 
 48 0·6 (1·1) 1·0 (1·1) 1·71 (1·23, 2·37) 0·0015 
Mean Lachrymal Flow (Schirmers I) (mm/5min) (Log-transformed 
a
) 
 16 2·0 (0·2) 2·2 (0·2) 1·19 (0·88, 1·61) 0·2624 
 24 2·2 (0·2) 2·2 (0·2) 1·01 (0·75, 1·35) 0·9642 
 36 2·1 (0·2) 2·3 (0·2) 1·09 (0·79, 1·51) 0·5926 
 48 2·0 (0·2) 2·2 (0·2) 1·16 (0·84, 1·61) 0·3698 
SF-36 – Physical Component Summary Score  
 24 38·2 (1·0) 36·3 (1·1) -1·86 (-4·15, 0·43) 0·1107 
 48 37·9 (1·0) 37·1 (1·1) -0·79 (-3·25, 1·67) 0·5246 
SF-36 – Mental Component Summary Score  
 24 41·7 (1·4) 41·0 (1·4) -0·64 (-3·81, 2·54) 0·6924 
 48 41·0 (1·6) 41·1 (1·5) 0·12 (-3·58, 3·82) 0·9495 
 
Footnotes: 
a – Salivary flow rates, mean lachrymal flow rates and ESSDAI scores were highly positively-
skewed, and so raw values were logarithm-transformed prior to analysis, and results back-
transformed for presentation.  
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Table	3:	Odds	ratios	for	the	effect	of	rituximab	relative	to	placebo	on	the	primary	
outcome,	and	the	interaction	between	subgroup	and	treatment	effect,	for	selected	
post-hoc	subgroups.		
Categorisation Adjusted Odds Ratio of Primary 
Endpoint response Rituximab 
vs Placebo (95% CI) 
Wald P-Value 
(For 
interaction) 
Baseline ESSDAI 5+ 0·55 (0·18, 1·73)  
Baseline ESSDAI 0-4 2·16 (0·65, 7·16)  
Interaction Effect (Relative OR) 0·26 (0·05, 1·33) 0·1044 
   
Baseline ESSDAI 14+ 1·27 (0·06, 26·44)  
Baseline ESSDAI 0-13 1·13 (0·49, 2·63)  
Interaction Effect (Relative OR) 1·12 (0·05, 26·01) 0·9441 
   
Years Since Diagnosis: 5+ 1·10 (0·31, 3·90)  
Years Since Diagnosis: 0-4 1·11 (0·38, 3·23)  
Interaction Effect (Relative OR) 1·00 (0·19, 5·35) 0·9969 
   
Baseline ESSPRI 5-10 1·16 (0·48, 2·80)  
Baseline ESSPRI 0-4 1·02 (0·14, 7·62)  
Interaction Effect (Relative OR) 1·14 (0·13, 10·07) 0·9086 
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Table	4:	Summary	of	numbers	of	Serious	Adverse	Events	and	Reactions	observed	
System Organ Class Event Placebo Rituximab 
TOTAL  10 10 
Serious Adverse Events    
Cardiac disorders Myocardial Infarction 1 - 
Endocrine disorders Hydatid Disease 1 - 
Gastrointestinal disorders Diarrhoea and Abdominal 
Pain 
1  
 Diarrhoea - 1 
 Abdominal Pain - 1 
Infections and infestations Pneumonia 1 - 
Metabolism & nutrition disorders Episode of Hypotensiveness - 1 
Musculoskeletal & connective tissue 
disorders 
Fractured bone - 1* 
 Swollen ankle - 1 
 Chest Pain 1 - 
Neoplasms Pancreatic Tumor - 1 
Renal and Urinary disorders EUA Cystoscopy and TVT 
Release 
1 - 
Respiratory, thoracic and mediastinal 
disorders 
Pulmonary Embolus 1 - 
Skin and Subcutaneous tissue disorders Malignant Melanoma - 1 
    
Serious Adverse Reactions    
Infections and Infestations Chest Infection 1 - 
 Sepsis - 1 
 Urinary Tract Infection - 1 
Injury, poisoning and procedural 
complications 
Anaphylaxis 1 - 
 Serious Infusion Reaction - 1 
Respiratory, thoracic and mediastinal Epiglotitis 1 - 
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disorders 
*-A patient randomised to receive rituximab withdrew prior to the first infusion. 
Subsequently, the patient reported a fall leading to a bone fracture. 
Note: one patient in the placebo arm, and one patient in the rituximab arm each reported 
two serious adverse Events 
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Figures:	
Figure	1:	Participant	flow	diagram	
 
Assessed for eligibility (n= 1253) 
Excluded Pre-registration (n= 1081) 
• Not meeting inclusion criteria (n= 678) 
• Declined to participate (n= 325) 
• Did Not Respond (n= 70) 
• Reason not given (n= 8) 
Excluded Post-registration (n=39) 
• Not eligible (n=23) 
• Withdrew consent / changed mind (n=12) 
• Other (n=4) 
Enrolment 
PLACEBO IV (250mL) 
Allocated to intervention   (n= 66) 
• Received all 4 infusions  (n= 55) 
• Received 3 infusions  (n= 3) 
• Received 2 infusions  (n= 7) 
• Received 1 infusion  (n= 1) 
• Received no infusions at all (n= 0) 
RITUXIMAB IV (1000mg in 250mL) 
Allocated to intervention   (n= 67) 
• Received all 4 infusions  (n= 54) 
• Received 3 infusions  (n= 3) 
• Received 2 infusions  (n= 4) 
• Received 1 infusion  (n= 4) 
• Received no infusions at all (n= 2) 
 
Allocation 
Randomised (n= 133) 
Analysed in full analysis dataset (n= 66) 
Included in Per-Protocol analysis dataset (n= 26)  
Excluded from PP analysis (n= 40) 
• Subsequently found to be ineligible (n=2) 
• Did not receive all 4 infusions (n=11) 
• Infusions outside accepted schedule (n=25) 
• Incomplete primary endpoint data (n=10) 
• Received one or more rituximab infusion (n= 0) 
Analysis 
Analysed in full analysis dataset (n= 67) 
Included in Per-Protocol analysis dataset (n= 26)  
Excluded from PP analysis (n= 41) 
• Subsequently found to be ineligible (n=4) 
• Did not receive all 4 infusions (n=13) 
• Infusions outside accepted schedule (n=27) 
• Incomplete primary endpoint data (n=6) 
• Received one or more Placebo infusion (n=0) 
Missing Primary Endpoint data (Baseline and 48 
weeks) (n= 10)  
• Omitted Baseline scales  (n= 1) 
• Did not attend week 48  (n= 8) 
• Attended week 48, missed VAS (n= 1) 
 
Attended week 16 follow-up visit (n= 62) 
Attended week 24 follow-up visit (n= 60) 
Attended week 36 follow-up visit (n= 59) 
Attended week 48 follow-up visit (n= 58) 
Follow-up 
Missing Primary Endpoint data (Baseline and 48 
weeks) (n= 6)  
• Omitted Baseline scales  (n= 1) 
• Did not attend week 48  (n= 4) 
• Attended week 48, missed VAS (n= 1) 
 
Attended week 16 follow-up visit (n= 64) 
Attended week 24 follow-up visit (n= 62) 
Attended week 36 follow-up visit (n= 60) 
Attended week 48 follow-up visit (n= 63) 
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Figure	2:	Mean	(95%	Confidence	Intervals)	values	of	(A)	Fatigue	VAS	(mm),	(B)	
Oral	Dryness	VAS	(mm),	(C)	Unstimulated	Salivary	Flow	(mL/15min),	(D)	
Lachrymal	Flow	(mm/5min).	Least-squares	means	adjusted	for	baseline	values,	
age,	disease	duration	and	substudy	consent	(left	axes)	and	between	group	
differences	(right	axes)	at	each	visit	(weeks).	Salivary	and	Lachrymal	flow	plotted	
on	Log2-scale.	Higher	VAS	values	(A,B)	indicate	worse	symptom	severity,	higher	
log-flow	rates	indicate	greater	salivary	or	lachrymal	flow.		The	region	in	which	a	
difference	favours	rituximab	(RTX)	is	annotated.		
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Short/Running	Title:	Rituximab	for	symptomatic	fatigue	and	
oral	dryness	in	Primary	Sjogrens	Syndrome.	
Title:	Randomized	Controlled	Trial	of	Rituximab	and	cost-
effectiveness	analysis	in	treating	fatigue	and	oral	dryness	in	
primary	Sjogren’s	Syndrome	
 
Online	Supplemental	Material	
A. Timing of patient attrition 
B. Cost effectiveness findings 
C. ESSDAI Domain level responses 
D. Additional Patient Symptomatic Response 
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Online	Supplement	A:	Timing	of	patient	attrition	
Footnote: Patients identified as “Did not attend” subsequently returned at a later date for 
one or more clinical assessments. Patients were lost to follow-up if they did not attend an 
assessment visit, nor any subsequent visits.  
 
 
  
PLACEBO IV (250mL) 
Allocated to intervention   (n= 66) 
RITUXIMAB IV (1000mg in 250mL) 
Allocated to intervention   (n= 67) 
 
Allocation 
Randomised (n= 133) 
Attended week 16 follow-up visit (n= 62) 
• Withdrew from follow-up (n=3) 
o Adverse Event (n=2) 
o Unwilling to continue (n=1) 
• Did not attend (n=1) 
 
Attended week 24 follow-up visit (n= 60) 
• Already withdrawn / lost (n=3) 
• Withdrew from follow-up (n=1) 
o Adverse Event 
• Did not attend (n=2) 
 
Attended week 36 follow-up visit (n= 59)  
• Already withdrawn / lost (n=4) 
• Withdrew from follow-up (n=2) 
o Unwilling to continue (n=2) 
• Did not attend (n=1) 
 
Attended week 48 follow-up visit (n= 58) 
• Attended in person (n=58) 
• Completed postal questionnaire instead (n=0) 
• Already withdrawn / lost (n=6) 
• Lost to follow-up (n=2) 
Follow-up 
Attended week 16 follow-up visit (n= 64) 
• Withdrew from follow-up (n=2) 
o Patient perceived lack of efficacy (n=1) 
o Adverse Event (n=1) 
• Lost to follow-up (n=1) 
 
Attended week 24 follow-up visit (n= 62) 
• Already withdrawn / lost (n=3) 
• Lost to follow-up (n=1) 
• Did not attend (n=1) 
 
 
Attended week 36 follow-up visit (n= 60) 
• Already withdrawn / lost (n=4) 
• Did not attend (n=3) 
 
 
 
Attended week 48 follow-up visit (n= 63) 
• Attended in person (n=60) 
• Completed postal questionnaire instead (n=3) 
• Already withdrawn / lost (n=4) 
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Online	Supplement	B	–	Cost	Effectiveness	findings	
Table	B1:	Probabilistic	QALYs	and	Costs	of	Rituximab	and	Placebo	
Treatment Arm QALYs: Mean QALYs: Std Dev Cost: Mean Cost: Std Dev 
Placebo 0·562 0·004 £2,672 241·71 
Rituximab 0·555 0·003 £10,752 264·75 
 
Figure	B1:	Cost-Effectiveness	Plane,	Rituximab	vs	Placebo	
Footnote: Positive values for incremental cost indicate that rituximab is more expensive 
than placebo. Positive values for incremental QALYs indicate that rituximab yields more 
quality of life than placebo.  
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Online	Supplement	C	–	ESSDAI	domain	changes	
Table	C1:	Constitutional	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Constitutional    
Improved 8 (12·1%) 8 (11·9%) 16 (12·0%) 
No change 50 (75·8%) 50 (74·6%) 100 (75·2%) 
Worsened 4 (6·1%) 4 (6·0%) 8 (6·0%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Constitutional    
Improved 5 (7·6%) 6 (9·0%) 11 (8·3%) 
No change 53 (80·3%) 50 (74·6%) 103 (77·4%) 
Worsened 2 (3·0%) 4 (6·0%) 6 (4·5%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Constitutional    
Improved 5 (7·6%) 6 (9·0%) 11 (8·3%) 
No change 48 (72·7%) 43 (64·2%) 91 (68·4%) 
Worsened 6 (9·1%) 9 (13·4%) 15 (11·3%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Constitutional    
Improved 7 (10·6%) 6 (9·0%) 13 (9·8%) 
No change 46 (69·7%) 48 (71·6%) 94 (70·7%) 
Worsened 4 (6·1%) 4 (6·0%) 8 (6·0%) 
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
    
 
Table	C2:	Lymphadenopathy	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Lymphadenopathy    
Improved 2 (3·0%) 9 (13·4%) 11 (8·3%) 
No change 56 (84·8%) 50 (74·6%) 106 (79·7%) 
Worsened 4 (6·1%) 3 (4·5%) 7 (5·3%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Lymphadenopathy    
Improved 2 (3·0%) 9 (13·4%) 11 (8·3%) 
No change 55 (83·3%) 47 (70·1%) 102 (76·7%) 
Worsened 3 (4·5%) 4 (6·0%) 7 (5·3%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Lymphadenopathy    
Improved 2 (3·0%) 9 (13·4%) 11 (8·3%) 
No change 53 (80·3%) 48 (71·6%) 101 (75·9%) 
Worsened 4 (6·1%) 1 (1·5%) 5 (3·8%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Lymphadenopathy    
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Improved 1 (1·5%) 7 (10·4%) 8 (6·0%) 
No change 54 (81·8%) 50 (74·6%) 104 (78·2%) 
Worsened 2 (3·0%) 1 (1·5%) 3 (2·3%) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
    
 
Table	C3:	Glandular	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Glandular    
Improved 10 (15·2%) 7 (10·4%) 17 (12·8%) 
No change 47 (71·2%) 50 (74·6%) 97 (72·9%) 
Worsened 5 (7·6%) 5 (7·5%) 10 (7·5%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Glandular    
Improved 14 (21·2%) 6 (9·0%) 20 (15·0%) 
No change 43 (65·2%) 49 (73·1%) 92 (69·2%) 
Worsened 3 (4·5%) 5 (7·5%) 8 (6·0%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Glandular    
Improved 13 (19·7%) 7 (10·4%) 20 (15·0%) 
No change 41 (62·1%) 49 (73·1%) 90 (67·7%) 
Worsened 5 (7·6%) 2 (3·0%) 7 (5·3%) 
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Glandular    
Improved 9 (13·6%) 8 (11·9%) 17 (12·8%) 
No change 46 (69·7%) 47 (70·1%) 93 (69·9%) 
Worsened 2 (3·0%) 3 (4·5%) 5 (3·8%) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
    
 
Table	C4:	Articular	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Articular    
Improved 9 (13·6%) 13 (19·4%) 22 (16·5%) 
No change 42 (63·6%) 44 (65·7%) 86 (64·7%) 
Worsened 11 (16·7%) 5 (7·5%) 16 (12·0%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Articular    
Improved 12 (18·2%) 12 (17·9%) 24 (18·0%) 
No change 43 (65·2%) 38 (56·7%) 81 (60·9%) 
Worsened 5 (7·6%) 10 (14·9%) 15 (11·3%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Articular    
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Improved 15 (22·7%) 16 (23·9%) 31 (23·3%) 
No change 36 (54·5%) 36 (53·7%) 72 (54·1%) 
Worsened 8 (12·1%) 6 (9·0%) 14 (10·5%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Articular    
Improved 12 (18·2%) 17 (25·4%) 29 (21·8%) 
No change 36 (54·5%) 35 (52·2%) 71 (53·4%) 
Worsened 9 (13·6%) 6 (9·0%) 15 (11·3%) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
    
 
Table	C5:	Cutaneous	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Cutaneous    
Improved 7 (10·6%) 3 (4·5%) 10 (7·5%) 
No change 52 (78·8%) 58 (86·6%) 110 (82·7%) 
Worsened 3 (4·5%) 1 (1·5%) 4 (3·0%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Cutaneous    
Improved 5 (7·6%) 3 (4·5%) 8 (6·0%) 
No change 50 (75·8%) 55 (82·1%) 105 (78·9%) 
Worsened 5 (7·6%) 2 (3·0%) 7 (5·3%) 
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Cutaneous    
Improved 4 (6·1%) 5 (7·5%) 9 (6·8%) 
No change 52 (78·8%) 52 (77·6%) 104 (78·2%) 
Worsened 3 (4·5%) 1 (1·5%) 4 (3·0%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Cutaneous    
Improved 5 (7·6%) 5 (7·5%) 10 (7·5%) 
No change 48 (72·7%) 51 (76·1%) 99 (74·4%) 
Worsened 4 (6·1%) 2 (3·0%) 6 (4·5%) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
    
 
Table	C6:	Respiratory	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Respiratory    
Improved 4 (6·1%) 3 (4·5%) 7 (5·3%) 
No change 58 (87·9%) 58 (86·6%) 116 (87·2%) 
Worsened - 1 (1·5%) 1 (0·8%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Respiratory    
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Improved 4 (6·1%) 3 (4·5%) 7 (5·3%) 
No change 53 (80·3%) 54 (80·6%) 107 (80·5%) 
Worsened 3 (4·5%) 3 (4·5%) 6 (4·5%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Respiratory    
Improved 2 (3·0%) 3 (4·5%) 5 (3·8%) 
No change 51 (77·3%) 51 (76·1%) 102 (76·7%) 
Worsened 6 (9·1%) 4 (6·0%) 10 (7·5%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Respiratory    
Improved 3 (4·5%) 3 (4·5%) 6 (4·5%) 
No change 50 (75·8%) 52 (77·6%) 102 (76·7%) 
Worsened 4 (6·1%) 2 (3·0%) 6 (4·5%) 
Either baseline / endpoint unknown 9 (13·6%) 10 (14·9%) 19 (14·3%) 
    
 
Table	C7:	Renal	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Renal    
Improved 2 (3·0%) - 2 (1·5%) 
No change 60 (90·9%) 62 (92·5%) 122 (91·7%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
    
Change from baseline for week 24 Renal    
Improved 2 (3·0%) - 2 (1·5%) 
No change 58 (87·9%) 59 (88·1%) 117 (88·0%) 
Either baseline / endpoint unknown 6 (9·1%) 8 (11·9%) 14 (10·5%) 
    
Change from baseline for week 36 Renal    
Improved 1 (1·5%) - 1 (0·8%) 
No change 58 (87·9%) 58 (86·6%) 116 (87·2%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Renal    
Improved 1 (1·5%) - 1 (0·8%) 
No change 56 (84·8%) 57 (85·1%) 113 (85·0%) 
Either baseline / endpoint unknown 9 (13·6%) 10 (14·9%) 19 (14·3%) 
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Table	C8:	Muscular	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Muscular    
No change 61 (92·4%) 62 (92·5%) 123 (92·5%) 
Worsened 1 (1·5%) - 1 (0·8%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Muscular    
No change 60 (90·9%) 60 (89·6%) 120 (90·2%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Muscular    
No change 59 (89·4%) 58 (86·6%) 117 (88·0%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Muscular    
No change 57 (86·4%) 57 (85·1%) 114 (85·7%) 
Worsened - 1 (1·5%) 1 (0·8%) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
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Table	C8:	Peripheral	Nervous	System	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 PNS    
Improved 2 (3·0%) 2 (3·0%) 4 (3·0%) 
No change 59 (89·4%) 59 (88·1%) 118 (88·7%) 
Worsened 1 (1·5%) 1 (1·5%) 2 (1·5%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 PNS    
Improved 2 (3·0%) 2 (3·0%) 4 (3·0%) 
No change 57 (86·4%) 58 (86·6%) 115 (86·5%) 
Worsened 1 (1·5%) - 1 (0·8%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 PNS    
Improved 2 (3·0%) 2 (3·0%) 4 (3·0%) 
No change 57 (86·4%) 56 (83·6%) 113 (85·0%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 PNS    
Improved 2 (3·0%) 2 (3·0%) 4 (3·0%) 
No change 55 (83·3%) 56 (83·6%) 111 (83·5%) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
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Table	C9:	Central	Nervous	System	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 CNS    
No change 62 (93·9%) 62 (92·5%) 124 (93·2%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 CNS    
No change 60 (90·9%) 60 (89·6%) 120 (90·2%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 CNS    
No change 59 (89·4%) 58 (86·6%) 117 (88·0%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 CNS    
No change 57 (86·4%) 58 (86·6%) 115 (86·5%) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
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Table	C10:	Haematological	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Haematological    
Improved 8 (12·1%) 6 (9·0%) 14 (10·5%) 
No change 50 (75·8%) 47 (70·1%) 97 (72·9%) 
Worsened 4 (6·1%) 9 (13·4%) 13 (9·8%) 
Either baseline / endpoint unknown 4 (6·1%) 5 (7·5%) 9 (6·8%) 
    
Change from baseline for week 24 Haematological    
Improved 7 (10·6%) 5 (7·5%) 12 (9·0%) 
No change 45 (68·2%) 45 (67·2%) 90 (67·7%) 
Worsened 8 (12·1%) 10 (14·9%) 18 (13·5%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Haematological    
Improved 8 (12·1%) 6 (9·0%) 14 (10·5%) 
No change 41 (62·1%) 42 (62·7%) 83 (62·4%) 
Worsened 10 (15·2%) 10 (14·9%) 20 (15·0%) 
Either baseline / endpoint unknown 7 (10·6%) 9 (13·4%) 16 (12·0%) 
    
Change from baseline for week 48 Haematological    
Improved 7 (10·6%) 3 (4·5%) 10 (7·5%) 
No change 42 (63·6%) 47 (70·1%) 89 (66·9%) 
Worsened 8 (12·1%) 7 (10·4%) 15 (11·3%) 
Either baseline / endpoint unknown 9 (13·6%) 10 (14·9%) 19 (14·3%) 
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Table	C11:	Biological	Domain	
 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Change from baseline for week 16 Biological    
Improved 17 (25·8%) 24 (35·8%) 41 (30·8%) 
No change 40 (60·6%) 35 (52·2%) 75 (56·4%) 
Worsened 4 (6·1%) 2 (3·0%) 6 (4·5%) 
Either baseline / endpoint unknown 5 (7·6%) 6 (9·0%) 11 (8·3%) 
    
Change from baseline for week 24 Biological    
Improved 15 (22·7%) 23 (34·3%) 38 (28·6%) 
No change 39 (59·1%) 36 (53·7%) 75 (56·4%) 
Worsened 6 (9·1%) 1 (1·5%) 7 (5·3%) 
Either baseline / endpoint unknown 6 (9·1%) 7 (10·4%) 13 (9·8%) 
    
Change from baseline for week 36 Biological    
Improved 16 (24·2%) 24 (35·8%) 40 (30·1%) 
No change 38 (57·6%) 32 (47·8%) 70 (52·6%) 
Worsened 5 (7·6%) 1 (1·5%) 6 (4·5%) 
Either baseline / endpoint unknown 7 (10·6%) 10 (14·9%) 17 (12·8%) 
    
Change from baseline for week 48 Biological    
Improved 15 (22·7%) 24 (35·8%) 39 (29·3%) 
No change 37 (56·1%) 30 (44·8%) 67 (50·4%) 
Worsened 5 (7·6%) 4 (6·0%) 9 (6·8%) 
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 Placebo (n=66) Rituximab (n=67) Total (n=133) 
Either baseline / endpoint unknown 9 (13·6%) 9 (13·4%) 18 (13·5%) 
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Online	Supplement	D	
Figure	D1:	Mean	(95%	Confidence	Intervals)	values	of	(A)	Ocular	Dryness	
VAS	(mm),	(B)	Overall	Dryness	VAS	(mm),	(C)	Pain	VAS	(mm),	(D)	Patient	
Global	Assessment	VAS	(mm).	Least-squares	means	adjusted	for	baseline	
values,	age,	disease	duration	and	substudy	consent	(left	axes)	and	between	
group	differences	(right	axes)	at	each	visit	(weeks).	Higher	VAS	values	
indicate	worse	symptom	severity.	The	region	in	which	a	difference	favours	
rituximab	(RTX)	is	annotated.	
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